So for the U.S. market the first 3 indications have about 10 times the registered Retts sufferers? With a drug that appears to be more effective and with less side effects than Daybue and therefore more likely to have both a higher take up and a greater retention rate it is difficult to understand the small value currently reflecting in the current SP. Add to this the company being profitable, cash rich and potentially many more indications to address it becomes more incomprehensible.
So for the U.S. market the first 3 indications have about 10...
-
- There are more pages in this discussion • 449 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.57 |
Change
-0.040(0.26%) |
Mkt cap ! $1.990B | |||
| Open | High | Low | Value | Volume |
| $15.83 | $15.87 | $15.20 | $8.124M | 524.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 64 | $15.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.58 | 597 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |